55 results about "Chronic inflammatory disease" patented technology

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

The present disclosure relates to smallpox vaccines and stem cells for treating diseases. Described herein are methods and compositions for treating an inflammatory disease or an infectious disease in a subject in need thereof by administering a poxvirus and a stem cell to the subject, wherein the disease is not a cancer. For example, the disease can be a chronic inflammatory disease (e.g., an autoimmune disease).

The application discloses a carbonyl heterocyclic compound and application thereof. The application provides a carbonyl heterocyclic compound as shown in formula II or a pharmaceutically acceptable salt thereof; the compound can be used as a compound with a targeted lipoamide synthetase C-like protein 2 path; and the compound can be used for treating various conditions, including infectious diseases, autoimmune diseases, diabetes and chronic inflammatory diseases.

The present invention relates to an inhibitor of CD74 protein activity or expression, for the therapeutic use thereof in the prevention and / or treatment of chronic inflammatory diseases including: chronic inflammatory rheumatisms, chronic inflammatory dermatoses, chronic inflammatory bowel diseases and chronic inflammatory neurological diseases. In another embodiment, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising six CDRs having the sequences SEQ ID NO. 3, 4, 5, 11, 12, and 13.

The invention provides an oral liquid based on algal oil-curcumin synergistic anti-inflammation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The oral liquid comprises the following raw materials: an anti-inflammatory agent (consisting of algae oil and curcumin), a traditional Chinese medicine extract (consisting of a herba houttuyniae extract and an Indian kalimeris herb extract), phospholipid, fructo-oligosaccharide, an antioxidant, a stabilizer (consisting of Arabic gum and hydroxypropyl-beta-cyclodextrin) and a flavoring agent. Experimental results show that the anti-inflammatory oral liquid is high in stability, and the content of inflammatory factors in mice with LPS-induced chronic inflammation can be remarkably reduced. The oral liquid can relieve chronic inflammation symptoms by regulating immune cell functions, blocking inflammation signal channels and other multi-target mechanisms, is high in safety after being used for a long time, does not have obvious adverse reaction, and provides a new choice for clinical treatment of chronic inflammatory diseases.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one short-lived radionuclide; a composition comprising said particle; said particle or composition for use as an imaging agent; said particle or composition for use in a method for the diagnosis of a proliferative disease; said particle or composition for use in a method for the diagnosis of a chronic inflammatory disease; and a kit comprising a particle comprising a MOF, an optional targeting moiety, and a short-lived radionuclide cation.

The present invention relates to a novel antagonistic anti-CD40 humanized antibody and, more specifically, to a novel humanized antibody specifically binding to CD40, which, by comprising a complementarity-determining region of a specific sequence, exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 humanized antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for suppressing immune rejection upon transplantation.

The application discloses a 1-aryl-5-pyrazolone compound and a pharmaceutical composition and application thereof. The compound has a structure selected from any one of the following structures, and also comprises a tautomer, a pharmaceutically acceptable salt or a mixture thereof: the compound can effectively inhibit COX-2 and effectively scavenge free radicals at a micromolar concentration level, can reduce cardiovascular and digestive tract side effects caused by NSAID-induced free radical production, and can also play a better treatment effect on chronic inflammatory diseases with pain through the synergistic effect of antioxidation stress and anti-inflammatory analgesia.

The present application relates to a novel anti-CD40 antibody and use thereof, and more particularly, to a novel anti-CD40 antibody comprising a complementarity determining region of a specific sequence, which exhibits an excellent antagonistic effect by blocking CD40-CD40L signal transduction, and use thereof. The novel anti-CD40 antibody of the present application exhibits an excellent antagonistic effect by blocking CD40-CD40L signal transduction, and thus can be widely used as a preparation for preventing or treating various diseases such as autoimmune diseases, chronic inflammatory diseases, etc., and a preparation for inhibiting immune rejection at the time of transplantation.

The present invention relates to a novel compound represented by Formula 1, functioning as a sphingosine-1-phosphate receptor agonist useful for treating autoimmune disorders, a preparation method therefor, a pharmaceutical composition containing the same as an active ingredient, and a use. The compound according to the present invention has an effect in extensive autoimmune diseases and chronic inflammatory diseases, including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulatory disorders.

The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysH) to produce compounds of interest. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.

The invention belongs to the technical field of nutrition fortifiers, and particularly relates to a nutrition fortifier containing kelp extract and a preparation method of the nutrition fortifier. The nutrition enhancer containing the kelp extract comprises the following components in parts by mass: 20-30 parts of the kelp extract, 50-60 parts of soybean protein powder, 5-15 parts of oat powder, 1-10 parts of inulin, 1-10 parts of sea cucumber powder and 1-5 parts of an undaria pinnatifida extract. The kelp extract is subjected to directional fermentation treatment by adopting a specific probiotic strain, so that the content and biological activity of fucoidin in the kelp extract are remarkably improved; meanwhile, a multi-level nutrition collaboration system is constructed; especially for chronic inflammatory diseases such as tumors, arthritis and psoriasis, the nutrition enhancer provides a safe and long-acting diet intervention scheme for specific people through anti-inflammatory and anti-angiogenesis dual-path effects, and has important clinical auxiliary application value.

The present disclosure relates to use of Atovaquone for treating and preventing acute and chronic inflammatory diseases in a mammal. The acute and chronic inflammatory diseases comprise mast cell-mediated inflammatory diseases.

The present application relates to pyrazole derivatives as inhibitors of the PD-1 / PD-L1 interaction. The applicants have designed compounds of general formula (I) wherein R ', R2, y3, R3, R4, R5, R6 and R7 are as defined herein, which are effective in blocking PD-1 / PD-L1 interactions to restore an anti-tumor immune response in a subject and eradicate any tumors in which dormant tumor cells and PD-L1 participate in immune escape. The inventor verifies that these compounds block the PD-1 / PD-L1 interaction by performing physical and chemical tests (MST, NanoDSF) and in vitro biological tests (FRET assay, Pralomig block assay, T cell assay). These compounds have affinity (Kd) in the order of pM, which Kd is higher than the Kd of the antibody Atezumab used in clinical use, and have IC50 comparable to or higher than that observed using Atezumab. Therefore, the invention also relates to a pharmaceutical composition containing the compound and application of the pharmaceutical composition in treatment of PD-1-PD-L1 interaction related diseases (cancers, chronic inflammatory diseases, neurological diseases and chronic infections).

This invention discloses a plasma-activated silver nanogel, its preparation method, and its application. The preparation method includes the following steps: S1, mixing silver nanoparticles with agarose solution, heating and reacting, and then allowing it to stand until it becomes a gel; S2, immersing the gel obtained in S1 in physiological saline; S3, subjecting the gel treated in S2 to plasma treatment to obtain the plasma-activated silver nanogel. The method of this invention locks the active particles in the gel before applying it to the skin surface, avoiding direct or close-range contact between the plasma generator and the skin, thus preventing skin burns and ensuring safety. Simultaneously, it synergistically enhances the effects of silver ions and ClO₂. ‑ It has a dual antibacterial mechanism, which relieves redness, swelling, and thickened scales, accelerates the resolution of inflammation, regulates the immune response, and relieves symptoms of chronic inflammatory diseases (such as psoriasis).

The invention discloses a small molecular compound targeting ZBP1 and application thereof, and belongs to the technical field of biological medicine. The small molecule compound targeting ZBP1 is 9 ''-salvianolic acid B monomethyl ester, the CAS number is 1167424-31-8, experiments verify that the 9''-salvianolic acid B monomethyl ester is combined with an RHIM structural domain of ZBP1, combination of ZBP1 with RIPK1 and RIPK3 is inhibited, and therefore downstream pathway activation is inhibited, and therefore the ZBP1 targeting inhibitor is provided and used for preparing a medicine for treating diseases caused by excessive activation of ZBP1, and the application prospect is wide. Such as autoinflammatory diseases, tissue damage and chronic inflammatory diseases. A small molecule compound 9 ''-salvianolic acid B monomethyl ester capable of being combined with ZBP1 is screened from an existing small molecule compound library, the effectiveness of targeted inhibition of ZBP1 expression is proved through experiments, and a new thought is provided for treating diseases caused by excessive activation of ZBP1.

A first aspect of the invention relates to a method of treating or preventing tissue damage, or treating or preventing tissue destruction, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase (sEH) inhibitor. A further aspect of the invention relates to a method of treating or preventing leishmaniasis in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a soluble epoxide hydrolase inhibitor.

This invention belongs to the field of nanomedicine delivery and immunotherapy technology, and provides a treatment for CD4-positive conditions including asthma, inflammatory bowel disease, and chronic sinusitis. + A CD4-targeting Runx3-siRNA nanodelivery system for T-cell-mediated chronic inflammatory diseases comprises lipid nanoparticles loaded with Runx3-siRNA and a CD4-targeting ligand coupled to the surface of the lipid nanoparticles. This system enables targeting of pathogenic CD4-mediated chronic inflammatory diseases. + T-cell-specific delivery and Runx3 gene silencing; lipid nanoparticles composed of ionic lipids, helper lipids, cholesterol, and PEG-modified lipids, with anti-CD4 antibodies anchored to the surface via maleimide-thiol coupling; this invention targets pathogenic CD4... + Specific delivery of T cells and silencing of the Runx3 gene solve the problems of side effects caused by non-specific immunosuppression and insufficient targeting of lipid nanoparticles.

The present invention relates to an inhibitor of CD74 protein activity or expression, for therapeutic use in the prevention and / or treatment of a chronic inflammatory disease selected from: chronic inflammatory rheumatic diseases, chronic inflammatory dermatoses, chronic inflammatory bowel diseases, and chronic inflammatory neurological diseases. In another aspect, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising at least one CD74 receptor (CDR) having a sequence selected from SEQ ID NO. 1 to 5.

The present invention relates to a human anti-FGF2 monoclonal antibody (mAb) comprising an amino acid sequence of a light chain as shown in SEQ ID NO: 1 or 3 and an amino acid sequence of a heavy chain as shown in SEQ ID NO: 2 or 4, in addition, the present invention relates to a pharmaceutical composition comprising said mAb and use thereof in the production of a medicament for treating cancer, in addition, the present invention relates to a kit for detecting FGF2 protein in a biological sample, the kit comprises the mAb or a biologically active fragment thereof bound to a detectable moiety, and can be used for prognosis or targeting cancer therapy, in addition to cancer-associated therapeutic applications such as inhibition of angiogenesis, potential applications of controlling fibrotic diseases, neutralizing excessive effects of FGF, and in particular, cancer-associated therapeutic applications such as inhibition of angiogenesis. The antibodies can be used in addition to their therapeutic potential in immunoscintillation photography, radioisotope labeling, for molecular imaging and prediction of fibrosis responses, for example in diseases of high intensity tissue repair (keloids) and secondary fibrosis of idiopathic fibrosis or chronic inflammatory disease.

The present invention relates to a method for predicting disease activity in patients with a chronic inflammatory disease, a method for identifying individual influencing factors on disease activity in chronic inflammatory diseases, and a method for reducing the frequency and / or intensity of disease flares in patients with a chronic inflammatory disease. The methods according to the invention enable a patient to prepare early for expected changes in disease activity and to identify influencing factors on disease activity based on their individual disease or symptom history.

The invention discloses an application of mitochondrial acid 5 in preparation of a product for enhancing the immunomodulatory ability of regulatory B cells, and provides a method for enhancing the immunomodulatory ability of the regulatory B cells. The regulatory B cells are pretreated by the mitochondrial acid 5, so that the expression of interleukin-10 in the regulatory B cells can be promoted, and the treatment effect of the regulatory B cells on autoimmune diseases, chronic inflammatory diseases and / or organ transplantation rejection can be enhanced; therefore, the invention also claims the protection of the application of mitochondrial acid 5 in the preparation of a synergist for a medicament for treating autoimmune diseases, chronic inflammatory diseases and / or organ transplant rejection. The invention develops a safe, efficient and specific method for promoting B lymphocyte to differentiate to functional Bregs and secrete interleukin-10, and the method can effectively inhibit over-active immune response and avoid self tissue damage.

The present invention provides compounds according to formula (I) as defined herein, or pharmaceutically acceptable salts or solvates thereof. The invention further provides pharmaceutical compositions comprising the compounds, and the use of the compounds or pharmaceutical compositions as a medicament, particularly for use in the treatment or prophylaxis of a disease or disorder selected from the group consisting of chronic inflammatory diseases, cancers, and parasitic diseases and infections.

The invention discloses a red blood cell artificial oxygen carrier therapeutic agent as well as a preparation method and application thereof. The therapeutic agent comprises a polyglutamic acid polymer initiated by methoxy polyethylene glycol, a stable composite structure is formed between polyglutamic acid and Prussian blue through coordination, electrostatic interaction and / or physical coating, and hemoglobin is grafted through amidation reaction. The preparation method comprises the following steps: synthesizing N-carbobenzoxy-L-glutamic acid N-carboxyl anhydride; initiating ring opening polymerization through mPEG-NH2, and performing deprotection to obtain mPEG-polyglutamic acid; a stable Prussian blue composite structure is formed through coordination, electrostatic interaction and / or physical coating; and finally, grafting hemoglobin. The compound has the functions of carrying oxygen and removing active oxygen, can perform long circulation in vivo and simulate red blood cells, is used for treating chronic inflammatory diseases combined with anemia, and can improve tissue hypoxia and relieve inflammatory response.